Mimivax looks for game-changer in GBM as SurVaxM shows signal of efficacy at interim look. (BioWorld Today Article)

Like David against Goliath, Roswell Park Comprehensive Cancer Center spinout Mimivax LLC is seeking to take down one of the most common and aggressive forms of brain cancer, and interim findings from its U.S. multicenter phase II study suggest the Buffalo-based company may have a shot.

MimiVax to present updated results of SurVaxM in newly diagnosed glioblastoma (Presented at ASCO 2019)

Updated median progression free survival (mPFS) is 15.5 months from diagnosis. Median overall survival (OS) is at 30.5 months from diagnosis. SurVaxM immunotherapy generated encouraging efficacy and immunogenicity in glioblastoma with minimal toxicity.

Company overview, including its accomplishments to date with SurVaxM and future plans (Presented at BIO 2019)

MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic targeted therapies for cancer. SurVaxM triggers T-cell immunity simultaneously with unique antibody-mediated anti-tumor responses.